Cross Country Healthcare to be Acquired by Knox Lane for $13.25 Per Share
Cross Country Healthcare (CCRN) has agreed to be acquired by private equity firm Knox Lane in an all-cash transaction. The deal is valued at approximately $437 million, with shareholders receiving $13.25 per share. This price represents a 31% premium over Cross Country Healthcare's closing stock price prior to the announcement.
The company's board of directors has unanimously recommended the transaction to its shareholders. A preliminary merger proxy statement has been filed with the U.S. Securities and Exchange Commission (SEC). The acquisition is subject to customary closing conditions, including regulatory approvals such as the HSR waiting period, and is anticipated to close in the third quarter of 2026.
Key Takeaways
- Cross Country Healthcare will be acquired by private equity firm Knox Lane for $13.25 per share in an all-cash transaction.stocktitan.netbusinesswire.comkirkland.comknoxlane.com
- The acquisition values Cross Country Healthcare at approximately $437 million and represents a 31% premium over its previous closing price.businesswire.comfiercehealthcare.comkirkland.com
- Cross Country Healthcare's board has recommended the deal, and a preliminary merger proxy statement has been filed with the SEC.stocktitan.netsec.gov
- The transaction is subject to regulatory approvals, including an HSR waiting period, and is expected to close in the third quarter of 2026.stocktitan.net
Sources
Preliminary Proxy Statement (DEF 14A)
SEC
“Cross Country Healthcare will file a definitive proxy statement on Schedule 14A in connection with the proposed transaction.”
Staffing firm Cross Country Healthcare to be acquired by Knox Lane for $437M
FierceHealthcare
“The acquisition prices Cross Country's stock at $13.25 per share, representing a 31% premium over its previous closing price.”
Cross Country Healthcare Inc. Preliminary Merger Proxy Statement
StockTitan
“Cross Country Healthcare agreed to be acquired for $13.25 cash per share, with the board recommending the deal and an expected close in Q3 2026.”